0-for-3 in PhI­II: Au­ris’ late-stage change­up fails to save tin­ni­tus drug from an­oth­er dis­as­ter

Eigh­teen months af­ter the hap­less Swiss biotech Au­ris Med­ical $EARS an­nounced its first Phase III study for its ex­per­i­men­tal drug Keyzilen (AM-101) for tin­ni­tus had flopped, its sec­ond late-stage study has al­so come in snake eyes — even though it re­vised the end­points and made the case it had good rea­son to be­lieve it was on track to win.

Win­ning, though, is not some­thing this com­pa­ny does much of.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER